Extraordinary meeting of the Pharmacovigilance Risk Assessment Committee (PRAC): 18 March 2021

EventHumanCOVID-19Pharmacovigilance

Swedish is available via eTranslation, the European Commission's machine translation service.

Translate to Swedish | Important information about machine translation

Date

torsdag, 18 mars 2021, Hela dagen

Plats

Online
European Medicines Agency, Amsterdam, the Netherlands

This extraordinary meeting is organised in the context of the evaluation of a safety signal with COVID-19 Vaccine AstraZeneca relating to cases of thromboembolic events.

The aim of the meeting is to conclude the evaluation of the signal based on the information gathered and make any necessary recommendations for further action.

The Pharmacovigilance Risk Assessment Committee (PRAC) is the European Medicines Agency's (EMA) committee responsible for assessing and monitoring the safety of human medicines.

Share this page